Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

PULSTA Transcatheter Pulmonary Valve Pre-Approval Study

NCT03983512 · tracked via the Priya Life Science Turkey tracker
Sponsor
Taewoong Medical Co., Ltd
Phase
Not applicable
Started
2019-10-07
Last updated
2026-04-13

Condition(s) studied

Heart DiseasesPulmonary Valve RegurgitationPulmonary Valve StenosisTetralogy of Fallot

Investigational drug(s) / intervention(s)

PULSTA TPV System

PULSTA TPV System: PULSTA transcatheter pulmonary valve replacement.

Study summary

The purpose of the study is to evaluate the safety and effectiveness of the PULSTA Transcatheter Pulmonary Valve (TPV) System for the treatment of congenital or acquired pulmonary valve stenosis and/or regurgitation who require pulmonary valve replacement.

Eligibility

Sex
ALL
Min age
10 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Body weight greater than or equal to 30 kilograms * Pulmonary regurgitation moderate or severe pulmonary regurgitation or pulmonary valve stenosis with mean gradient \>35mmHg by echocardiography * Main pulmonary artery trunk of ≥16 mm and ≤30 mm * Patients willing to provide written informed consent and comply with follow-up evaluations. Exclusion Criteria: * Females of child-bearing potential who are unable to take adequate contraceptive precautions, are known to be pregnant, or are currently breastfeeding an infant up until 6 months after TPV implantation * Pre-existing mechanical valve in pulmonary position or require concomitant repair of other cardiac valves * Obstruction of the central veins to be approached for the TPV implantation * Coronary artery compression confirmed by angiography * A known severe allergy to Nickel * A known hypersensitivity to any anticoagulation therapy, contrast agent or a hemorrhagic disease * Suspected active infectious disease (e.g. endocarditis, meningitis) * Life expectancy of less than 6 months

Primary outcome measure(s)

  • Procedural/Device related serious adverse events at 6 months — 6 months
  • Hemodynamic functional improvement at 6 months — 6 months
    Hemodynamic functional improvement is a composite of mean RVOT gradient ≤30 mmHg by continuous wave Doppler and a pulmonary regurgitant fraction \<20% by cardiac magnetic resonance (MR)

Trial sites (11)

FacilityCityRegionStatus
Deutsches Herzzentrum Munchen München München
Policlinico San Donato Milan San Donato Milanese
Utrecht University Wilhelmina Utrecht Utrecht
Erasmus Medical Center Rotterdam Wytemaweg
Seoul National University Hospital Seoul Daehak-ro Jongno-gu
Sejong General Hospital Bucheon-si Hohyun-ro, Sosa-gu
Severance Hospital Seoul Yonsei-ro, Seodaemun-gu
Gregorio Marañon hospital Madrid Madrid
University Hospital La Paz Madrid Madrid
Koc University Hospital Istanbul Topkapı, Zetinburnu/İstanbul
Siyami Ersek Hospital Istanbul Üsküdar/İstanbul

More Taewoong Medical Co., Ltd. trials in Turkey

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03983512 on ClinicalTrials.gov ↗ ← All trials in Turkey